Technology | October 16, 2007

Anesiva Receives FDA Approval for Zingo

Anesiva Inc. recently announced the FDA has approved Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system, which provides rapid, topical, local analgesia to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children ages three to 18.

Zingo is an easy-to-administer, single-use, needle-free system containing 0.5 mg sterile lidocaine powder. It provides a rapid onset of action, allowing intravenous line placement or venipuncture to begin one to three minutes after administration.
Study data indicated that treatment with Zingo quickly and effectively reduced pain.

Overlay Init